Johannes Ruediger Kratz

Dr. Johannes Ruediger Kratz

Surgery, University of California, San Francisco, San Francisco, California, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2020 in Cell
Verified
Journal Article
Open access
AMAshley Maynard
Ashley Maynard
CMCaroline E. McCoach
Caroline E. McCoach
JRJulia K. Rotow
Julia K. Rotow
LHLincoln Harris
Lincoln Harris
FHFranziska Haderk
Franziska Haderk
TBTrever Bivona
Trever Bivona
Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables adaptability, limits therapeutic success, and remains incompletely understood. Single-cell RNA sequencing (scRNA-seq) of metastatic lung cancer was performed using 49 clinical biopsies obtained from 30 patients before and during targeted therapy. Over 20,000 cancer and tumor microenvironment (TME) single-cell profiles exposed a rich and dynamic tumor ecosystem. scRNA-seq of cancer cells illuminated targetable oncogenes beyond those detected clinically. Cancer cells surviving therapy as residual disease (RD) expressed an alveolar-regenerative cell signature suggesting a therapy-induced primitive cell-state transition, whereas those present at on-therapy progressive disease (PD) upregulated kynurenine, plasminogen, and gap-junction pathways. Active T-lymphocytes and decreased macrophages were present at RD and immunosuppressive cell states characterized PD. Biological features revealed by scRNA-seq were biomarkers of clinical outcomes in independent cohorts. This study highlights how therapy-induced adaptation of the multi-cellular ecosystem of metastatic cancer shapes clinical outcomes.

8 December 2005 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
KPKush M. Parmar
Kush M. Parmar
HLH. Benjamin Larman
H. Benjamin Larman
GDGuohao Dai
Guohao Dai
YZYuzhi Zhang
Yuzhi Zhang
EWEric T. Wang
Eric T. Wang
GGGuillermo García-Cardeña
Guillermo García-Cardeña
In the face of systemic risk factors, certain regions of the arterial vasculature remain relatively resistant to the development of atherosclerotic lesions. The biomechanically distinct environments in these arterial geometries exert a protective influence via certain key functions of the endothelial lining; however, the mechanisms underlying the coordinated regulation of specific mechano-activated transcriptional programs leading to distinct endothelial functional phenotypes have remained elusive. Here, we show that the transcription factor Kruppel-like factor 2 (KLF2) is selectively induced in endothelial cells exposed to a biomechanical stimulus characteristic of atheroprotected regions of the human carotid and that this flow-mediated increase in expression occurs via a MEK5/ERK5/MEF2 signaling pathway. Overexpression and silencing of KLF2 in the context of flow, combined with findings from genome-wide analyses of gene expression, demonstrate that the induction of KLF2 results in the orchestrated regulation of endothelial transcriptional programs controlling inflammation, thrombosis/hemostasis, vascular tone, and blood vessel development. Our data also indicate that KLF2 expression globally modulates IL-1β–mediated endothelial activation. KLF2 therefore serves as a mechano-activated transcription factor important in the integration of multiple endothelial functions associated with regions of the arterial vasculature that are relatively resistant to atherogenesis.

1 March 2012 in The Lancet
Verified
Journal Article
Closed access
JKJohannes Ruediger Kratz
Johannes Ruediger Kratz
JHJianxing He
Jianxing He
SEStephen K Van Den Eeden
Stephen K Van Den Eeden
ZZZhi-Hua Zhu
Zhi-Hua Zhu
WGWen Gao
Wen Gao
DJDavid M Jablons
David M Jablons

27 December 2021 in Cell
Verified
Journal Article
Closed access
ACAlexis J. Combes
Alexis J. Combes
BSBushra Samad
Bushra Samad
JTJessica Tsui
Jessica Tsui
NCNayvin W. Chew
Nayvin W. Chew
PYPeter Yan
Peter Yan
MKMatthew F. Krummel
Matthew F. Krummel

1 October 2004 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
EAElena Aikawa
Elena Aikawa
MAMasanori Aikawa
Masanori Aikawa
MFMark Farber
Mark Farber
JKJohannes Ruediger Kratz
Johannes Ruediger Kratz
GGGuillermo Garcia-Cardena
Guillermo Garcia-Cardena
FSFrederick J. Schoen
Frederick J. Schoen

10 September 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CBCollin M. Blakely
Collin M. Blakely
AUAnatoly Urisman
Anatoly Urisman
MGMatthew A. Gubens
Matthew A. Gubens
CMClaire K. Mulvey
Claire K. Mulvey
GAGreg M. Allen
Greg M. Allen
DJDavid M. Jablons
David M. Jablons
PURPOSE: To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA EGFR-mutated non–small cell lung cancer (NSCLC). PATIENTS AND METHODS: This was a multi-institutional phase II trial of neoadjuvant osimertinib for patients with surgically resectable stage I-IIIA (American Joint Committee on Cancer [AJCC] V7) EGFR-mutated (L858R or exon 19 deletion) NSCLC (ClinicalTrials.gov identifier: NCT03433469 ). Patients received osimertinib 80 mg orally once daily for up to two 28-day cycles before surgical resection. The primary end point was major pathological response (MPR) rate. Secondary safety and efficacy end points were also assessed. Exploratory end points included pretreatment and post-treatment tumor mutation profiling. RESULTS: A total of 27 patients were enrolled and treated with neoadjuvant osimertinib for a median 56 days before surgical resection. Twenty-four (89%) patients underwent subsequent surgery; three (11%) patients were converted to definitive chemoradiotherapy. The MPR rate was 14.8% (95% CI, 4.2 to 33.7). No pathological complete responses were observed. The ORR was 52%, and the median DFS was 40.9 months. One treatment-related serious adverse event (AE) occurred (3.7%). No patients were unable to undergo surgical resection or had surgery delayed because of an AE. The most common co-occurring tumor genomic alterations were in TP53 (42%) and RBM10 (21%). CONCLUSION: Treatment with neoadjuvant osimertinib in surgically resectable (stage IA-IIIA, AJCC V7) EGFR-mutated NSCLC did not meet its primary end point for MPR rate. However, neoadjuvant osimertinib did not lead to unanticipated AEs, surgical delays, nor result in a significant unresectability rate.